XML 39 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Note 1 - Summary of Operations and Significant Accounting Policies 1 (Details Textual)
$ in Thousands
12 Months Ended
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Capitalized Contract Cost, Gross | $ $ 0 $ 0
Research and Development Expense, Gross | $ 7,874 8,042
Customer Funded Research and Development Expense Included in Cost of Goods Sold | $ $ 793 $ 1,216
Number of Operating Segments 2  
Share-Based Payment Arrangement, Option [Member]    
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements | shares 0 0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares 1,425,693 1,306,824
Restricted Stock [Member]    
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements | shares 0 0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares 2,500 11,664
Customer Concentration Risk [Member] | Revenue Benchmark [Member]    
Number of Major Customers 1 1
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Large Defense Primary Contractor, 1 [Member]    
Concentration Risk, Percentage 17.00% 20.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Large Defense Primary Contractor, 1 [Member] | Battery & Energy Products Segment [Member]    
Concentration Risk, Percentage 19.00% 22.00%
Minimum [Member]    
Standard Product Warranty, Period 90 days  
Maximum [Member]    
Standard Product Warranty, Period 3 years  
Extended Warranty Contracts [Member]    
Extended Product Warranty, Period 8 years  
Revenue, Remaining Performance Obligation, Amount | $ $ 682